• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

美国人类免疫缺陷病毒感染的青少年和成人原发性卡氏肺孢子虫肺炎的危险因素:对化学预防指征的重新评估。

Risk factors for primary Pneumocystis carinii pneumonia in human immunodeficiency virus-infected adolescents and adults in the United States: reassessment of indications for chemoprophylaxis.

作者信息

Kaplan J E, Hanson D L, Navin T R, Jones J L

机构信息

Division of HIV/AIDS Prevention-Surveillance and Epidemiology, Centers for Disease Control and Prevention, Atlanta, Georgia 30333, USA.

出版信息

J Infect Dis. 1998 Oct;178(4):1126-32. doi: 10.1086/515658.

DOI:10.1086/515658
PMID:9806044
Abstract

Risk factors for the development of a first episode of Pneumocystis carinii pneumonia (PCP) were investigated in the Adult and Adolescent Spectrum of Disease Project, a medical record review study involving longitudinal follow-up of human immunodeficiency virus-infected adults in 9 US cities. Risk factors included decreasing CD4 lymphocyte count and history of AIDS-defining illness, non-P. carinii pneumonia, oral thrush, or unexplained fever for > or = 2 days; PCP prophylaxis was protective. PCP incidence/100 person-years of observation among persons not prescribed PCP prophylaxis was higher in those with CD4 lymphocyte counts < 250 cells/microL or CD4 cell percent < 14% (8.3; 95% confidence interval [CI], 7.7-9.0) than in persons with CD4 cell counts < 200 or history of thrush or fever, which constitute current criteria for prophylaxis against PCP (5.9; 95% CI, 5.5-6.4). Because of increased efficiency in capturing persons at highest risk, CD4 cell count < 250 or CD4 cell percent < 14% should be considered as criteria for prophylaxis against first episodes of PCP.

摘要

在成人及青少年疾病谱项目中,对卡氏肺孢子虫肺炎(PCP)首发的危险因素进行了调查。该项目是一项病历回顾研究,涉及对美国9个城市感染人类免疫缺陷病毒的成年人进行纵向随访。危险因素包括CD4淋巴细胞计数下降以及艾滋病界定疾病史、非卡氏肺孢子虫肺炎、鹅口疮或不明原因发热≥2天;PCP预防具有保护作用。在未接受PCP预防的人群中,CD4淋巴细胞计数<250个/微升或CD4细胞百分比<14%的人群中PCP发病率/100人年观察期(8.3;95%置信区间[CI],7.7 - 9.0)高于CD4细胞计数<200或有鹅口疮或发热史的人群,后者构成当前PCP预防标准(5.9;95%CI,5.5 - 6.4)。由于在捕捉高危人群方面效率提高,CD4细胞计数<250或CD4细胞百分比<14%应被视为预防PCP首发的标准。

相似文献

1
Risk factors for primary Pneumocystis carinii pneumonia in human immunodeficiency virus-infected adolescents and adults in the United States: reassessment of indications for chemoprophylaxis.美国人类免疫缺陷病毒感染的青少年和成人原发性卡氏肺孢子虫肺炎的危险因素:对化学预防指征的重新评估。
J Infect Dis. 1998 Oct;178(4):1126-32. doi: 10.1086/515658.
2
Is it safe to discontinue primary Pneumocystis jiroveci pneumonia prophylaxis in patients with virologically suppressed HIV infection and a CD4 cell count <200 cells/microL?对于病毒学抑制的 HIV 感染且 CD4 细胞计数<200 个/μL 的患者,停止原发性卡氏肺孢子虫肺炎预防是否安全?
Clin Infect Dis. 2010 Sep 1;51(5):611-9. doi: 10.1086/655761.
3
Prophylaxis against Pneumocystis carinii pneumonia among children with perinatally acquired human immunodeficiency virus infection in the United States. Pneumocystis carinii Pneumonia Prophylaxis Evaluation Working Group.美国围产期获得性人类免疫缺陷病毒感染儿童中卡氏肺孢子虫肺炎的预防。卡氏肺孢子虫肺炎预防评估工作组。
N Engl J Med. 1995 Mar 23;332(12):786-90. doi: 10.1056/NEJM199503233321206.
4
Pneumocystis carinii pneumonia recurrence in HIV patients on highly active antiretroviral therapy: secondary prophylaxis.接受高效抗逆转录病毒治疗的艾滋病患者中卡氏肺孢子虫肺炎的复发:二级预防
J Acquir Immune Defic Syndr. 2001 Feb 1;26(2):151-8. doi: 10.1097/00042560-200102010-00007.
5
A randomized trial of the discontinuation of primary and secondary prophylaxis against Pneumocystis carinii pneumonia after highly active antiretroviral therapy in patients with HIV infection. Grupo de Estudio del SIDA 04/98.一项关于HIV感染患者接受高效抗逆转录病毒治疗后停止卡氏肺孢子虫肺炎一级和二级预防的随机试验。艾滋病研究小组04/98。
N Engl J Med. 2001 Jan 18;344(3):159-67. doi: 10.1056/NEJM200101183440301.
6
Recommendations for prophylaxis against Pneumocystis carinii pneumonia for adults and adolescents infected with human immunodeficiency virus.
MMWR Recomm Rep. 1992 Apr 10;41(RR-4):1-11.
7
Thrush and fever as measures of immunocompetence in HIV-1-infected men.鹅口疮和发热作为HIV-1感染男性免疫能力的衡量指标。
J Acquir Immune Defic Syndr (1988). 1994 Dec;7(12):1242-9.
8
Discontinuation of chemoprophylaxis against Pneumocystis carinii pneumonia in patients with HIV infection. HIV Outpatient Study (HOPS) Investigators.HIV感染患者中卡氏肺孢子虫肺炎化学预防的停用。HIV门诊研究(HOPS)研究者。
Ann Intern Med. 2000 Feb 1;132(3):201-5. doi: 10.7326/0003-4819-132-3-200002010-00005.
9
Predictors for failure of Pneumocystis carinii pneumonia prophylaxis. Multicenter AIDS Cohort Study.卡氏肺孢子虫肺炎预防失败的预测因素。多中心艾滋病队列研究。
JAMA. 1995 Apr 19;273(15):1197-202.
10
Discontinuation of prophylaxis for Pneumocystis carinii pneumonia in HIV-1-infected patients treated with highly active antiretroviral therapy.接受高效抗逆转录病毒治疗的HIV-1感染患者卡氏肺孢子虫肺炎预防性治疗的停药情况。
Lancet. 1999 Jan 16;353(9148):201-3. doi: 10.1016/S0140-6736(98)07204-3.

引用本文的文献

1
An AIDS Patient With Pneumocystis jiroveci Pneumonia.一名患有耶氏肺孢子菌肺炎的艾滋病患者。
Cureus. 2025 Jun 17;17(6):e86237. doi: 10.7759/cureus.86237. eCollection 2025 Jun.
2
Risk of Pneumonia in Patients With HIV in Taiwan: Evidence from a Cross-sectional Study.台湾地区HIV患者的肺炎风险:一项横断面研究的证据。
In Vivo. 2025 Mar-Apr;39(2):1054-1066. doi: 10.21873/invivo.13910.
3
Pneumocystis jirovecii Pneumonia and HIV-Associated Nephropathy in Acute HIV Infection.急性HIV感染中的耶氏肺孢子菌肺炎和HIV相关性肾病
Cureus. 2024 Sep 11;16(9):e69189. doi: 10.7759/cureus.69189. eCollection 2024 Sep.
4
Localized Pneumocystis jirovecii pneumonia in a malnourished, non-HIV-infected man in the absence of any established or diagnosed immunosuppressive condition: a case report.营养状况不佳的非 HIV 感染男性患者中出现局限性肺孢子菌肺炎,但无任何既定或确诊的免疫抑制状态:病例报告。
BMC Pulm Med. 2024 Oct 7;24(1):489. doi: 10.1186/s12890-024-03308-y.
5
pneumonia in people living with HIV: a review.HIV 感染者肺炎:综述。
Clin Microbiol Rev. 2024 Mar 14;37(1):e0010122. doi: 10.1128/cmr.00101-22. Epub 2024 Jan 18.
6
HIV-associated lung disease.HIV 相关肺部疾病。
Nat Rev Dis Primers. 2023 Jul 27;9(1):39. doi: 10.1038/s41572-023-00450-5.
7
Prophylaxis for Pneumocystis jirovecii pneumonia in patients with inflammatory bowel disease: A systematic review.炎症性肠病患者中预防卡氏肺孢子虫肺炎:系统评价。
Pharmacotherapy. 2022 Nov;42(11):858-867. doi: 10.1002/phar.2733. Epub 2022 Oct 25.
8
Trends in the Epidemiology and Outcomes of Pneumocystis Pneumonia among Human Immunodeficiency Virus (HIV) Hospitalizations.人类免疫缺陷病毒(HIV)住院患者中肺囊虫肺炎的流行病学和结局趋势。
Int J Environ Res Public Health. 2022 Feb 27;19(5):2768. doi: 10.3390/ijerph19052768.
9
No need for secondary Pneumocystis jirovecii pneumonia prophylaxis in adult people living with HIV from Europe on ART with suppressed viraemia and a CD4 cell count greater than 100 cells/µL.无需对接受抗逆转录病毒治疗(ART)后病毒血症得到抑制且 CD4 细胞计数大于 100 个/µL 的欧洲成人 HIV 感染者进行继发性卡氏肺孢子菌肺炎预防。
J Int AIDS Soc. 2021 Jun;24(6):e25726. doi: 10.1002/jia2.25726.
10
It's not all about COVID-19: pneumocystis pneumonia in the era of a respiratory outbreak.并非一切都与新冠病毒有关:呼吸道疾病爆发时代的肺孢子菌肺炎。
J Int AIDS Soc. 2020 Jun;23(6):e25533. doi: 10.1002/jia2.25533.